



**Q4 2020 Preview and Overview of Amend
and Extend Exchange Offer**

Disclaimer

This presentation has been prepared by the management of LSF9 Balta Issuer S.à r.l (the “Company”) for information purposes only. In considering any performance information contained herein, you should bear in mind that past or projected performance is not necessarily indicative of future results, and there can be no assurance that any entity referenced herein will achieve comparable results or that illustrative returns, if any, will be met. Statements in this presentation are made as of the date this presentation is made unless stated otherwise, and the delivery of this presentation at any time shall under no circumstances create an implication that the information contained herein is correct as of any time after such date.

This presentation contains statements that, to the extent they are not recitations of historical fact, constitute “forward-looking statements”. Actual outcomes and results could differ materially from those forecasts due to the impact of many factors beyond the control of the Company and its affiliates. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements, which are other than statements of historical facts. The words “believe”, “expect”, “anticipate”, “intends”, “plan”, “estimate”, “aim”, “forecast”, “project”, “will”, “may”, “might”, “should”, “could” and similar expressions (or their negative) identify certain of these forward-looking statements. Forward-looking statements include statements regarding: business strategies, outlook and growth prospects; future plans and potential for future growth; growth in demand for soft flooring products; expected developments in production capabilities, including technological advancements in soft flooring manufacturing; expected spending by our customers and competitors; liquidity, capital resources and capital expenditures; economic outlook and industry trends; developments of markets; the impact of regulatory initiatives; and the strength of competitors. No statement in this presentation is intended to be nor may be construed as a profit forecast.

The forward-looking statements in this presentation are based upon various assumptions, many of which are based, in turn, upon further assumptions, including without limitation, management's examination of historical operating trends, data contained in the Company's records and other data available from third parties. These assumptions are inherently subject to significant uncertainties and contingencies which are difficult or impossible to predict and are beyond its control and it may not achieve or accomplish these expectations, beliefs or projections. In addition, important factors that, in the view of the Company, could cause actual results to differ materially from those discussed in the forward-looking statements include the COVID-19 pandemic, the achievement of the anticipated levels of profitability, growth, the impact of competitive pricing, shifts in customer, market and consumer demand, competition risk, regulatory risk, financial markets risk, operational risks, the impact of general business, European and Belgian economic conditions and other risks and factors. In this presentation, we have not factored in any potential near-term disruption to our business as a result of the recent COVID-19 resurgence and resultant lockdowns across our markets. Our business and our actual results may differ from the information presented below and our results may not be as favorable as described below. In light of these risks, uncertainties and assumptions, the forward-looking statements contained in this document might not prove to be accurate and you should not place undue reliance upon them. All forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by the foregoing cautionary statements. Figures contained in the presentation may be rounded.

This presentation does not constitute an offer to sell or the solicitation of an offer to buy any securities, including the New Notes referred herein, in any jurisdiction and shall not, in any circumstance, constitute an offer, solicitation or sale in the United States or in any jurisdiction in which, or to any persons to whom, such offering, solicitation or sale would be unlawful. The New Notes have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the “Securities Act”), or any U.S. state securities laws, and may not be offered or sold within the United States or to, or for the account or benefit of, U.S. persons except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and applicable state and local securities laws. Accordingly, the New Notes will be offered and sold only to (i) qualified institutional buyers in accordance with Rule 144A under the Securities Act, (ii) institutional “accredited investors” (within the meaning of Rule 501(a)((1), (2), (3), (7), (8), (9), (12) or (13), under the Securities Act and (ii) to non-U.S. persons outside the United States in offshore transactions in accordance with Regulation S under the Securities Act.

The New Notes are not intended to be offered, sold or otherwise made available to and should not be offered, sold or otherwise made available to any retail investor in the EEA or the United Kingdom. For these purposes, a retail investor means a person who is one (or more) of: (i) a retail client as defined in point (11) of Article 4(1) of Directive 2014/65/EU (as amended, “MIFID II”); or (ii) a customer within the meaning of Directive (EU) 2016/97 (as amended or superseded, the “Insurance Distribution Directive”), where that customer would not qualify as a professional client as defined in point (10) of Article 4(1) of MIFID II; or (iii) not a qualified investor as defined in Regulation (EU) 2017/1129 (the “Prospectus Regulation”). The offer and sale of the New Notes will be made pursuant to an exemption under the Prospectus Regulation from the requirement to produce a prospectus for offers of securities. Consequently, no key information document required by Regulation (EU) no 1286/2014 (as amended, the “PRIIPS Regulation”) for offering or selling the New Notes or otherwise making them available to retail investors in the EEA or the United Kingdom has been prepared and therefore offering or selling the New Notes or otherwise making them available to any retail investor in the EEA or the United Kingdom may be unlawful under the PRIIPS Regulation. References to regulations or directives include, in relation to the United Kingdom, those regulations or directives as they form part of U.K. domestic law by virtue of the European Union (Withdrawal) Act 2018 or have been implemented in U.K. domestic law, as appropriate.

Certain financial data included in this presentation are “non-IFRS financial measures.” These non-IFRS financial measures may not be comparable to similarly titled measures presented by other entities, nor should they be construed as an alternative to other financial measures determined in accordance with International Financial Reporting Standards. Although the Company believes these non-IFRS financial measures provide useful information to users in measuring the financial performance and condition of its business, users are cautioned not to place undue reliance on any non-IFRS financial measures or any ratios included in this presentation. The financial information included in this document includes figures that have not been subject to an audit or review by any independent auditor in accordance with generally accepted auditing standards. In particular, the financial preview for the quarter and year ended December 31, 2020 included herein is that of the Balta Group NV, as provided by its management and is subject to audit review. This presentation also includes certain unaudited pro forma consolidated financial information. The unaudited pro forma adjustments are based upon available information and certain assumptions that the Company's management believes to be reasonable. The assumptions underlying the pro forma adjustments have not been audited or reviewed in accordance with any generally accepted auditing standards.



 **balta**

Q4 2020 Trading Preview

Q4 20 Financial Preview

Continued recovery into Q4 20, substantially outperforming Q4 19 profitability

(8%)
YoY sales growth
(consolidated)

- Expected Q4 20 Consolidated revenue of €151m
- Top-line growth in Rugs (+1%) and Residential (+10%), while Commercial (-25%) still impacted by COVID-19 slowdowns

+41%
YoY Adjusted EBITDA growth

- Expected Q4 20 Consolidated Adjusted EBITDA of €28m
- Adjusted EBITDA growth driven by margin improvement from 12% to 18%:
 - Positive and recurring NEXT contribution
 - Continued fixed expense savings
 - Low raw material price environment



4.2x
Leverage
Excluding IFRS16
(on a like-for-like basis)

€247m
Net Debt
(excl. IFRS16, incl. accrued interest)

- Continued leverage reduction from 5.9x in Q2 20 and 4.7x in Q3 20
- Reported net debt excludes €36m impact from IFRS16
- Net debt before the impact of IFRS16 down from H1 20, as result of strong cash generation through working capital reduction and strong quarterly Adjusted EBITDA in Q3 and Q4

FY20 Financial Progression


Performance rebounding strongly into Q3 and Q4 20, post COVID-19 disruption



Q4 20 figures presented show preliminary flash results prepared by Balta Group to represent the latest estimate of company performance – subject to audit review

Q4 20 Leverage expected to be 4.2x, excluding IFRS16

Strong liquidity and reducing leverage through effective WC management and Adjusted EBITDA growth



- Leverage in FY20 negatively impacted by COVID-19 disruption
- Effective cost and working capital management mitigated the impact, with continued improvements, alongside Adjusted EBITDA recovery, generating quarter on quarter leverage reduction
- Q4 20 leverage expected to be 4.2x
- Strong total liquidity incl. undrawn RCF facilities of €114m at the end of Q4, after settlement c.€13m social security charges deferred from Q2 and c.€26m Capex for the year
- Continued progression through market recovery from COVID-19 is expected to further reduce leverage alongside company initiatives alongside market recovery from COVID-19 is expected to further reduce leverage

Note: Debt figures include accrued interest (€5m as of Dec-20), numbers may not add up due to rounding

¹ Leverage ratios based on latest estimate of FY20 Adj. EBITDA excl. IFRS16 of €59m – subject to audit review

² €106m cash, €7m undrawn RCF as of Dec-20, RCF remained fully undrawn during FY19

³ Adjusted EBITDA excl. IFRS16 impact

Further financial information regarding the exchange offer, the company's pro forma capitalization giving effect to the exchange offer and information on its strategies and forecasts are set forth in the exchange offer information pack separately made available by the company



 **balta**

Exchange Offer
7.75% Senior Secured Notes, due 2022

Introduction to Exchange Offer

We are pleased to launch an exchange offer for the 7.75% Senior Secured Notes, due 2022 (“SSNs”)

Key Features

- Exchange offer with choice between two options;
 - I. Exchange all SSNs for equivalent face value of new notes due 31 December 2024 (“New Notes”); or
 - II. Exchange SSNs for a portion of €39.2m cash allocated pro rata to SSNs selecting this option at a price of €980 cash for each €1,000 principal SSNs tendered, with remainder of SSNs exchanged for New Notes at full face value¹⁾
- European SSRCF maturity to amend from June 2022 to June 2024 in accordance with its terms
- 0.75% fee for all consenting SSNs exchanged for New Notes under either option (but not SSNs that receive cash), of which 0.5% ‘early bird’
- 1% PIK uplift in coupon for New Notes, increasing to 3% from March 2024
- Call at 102 only in the case of a refinancing in the first 6 months, then par call, then 102 call premium for any repayment from March 2023 until maturity
- Enhanced security package and documentary protection for New Notes

Attractive offer which benefits both SSNs and the company

- Effective extension of maturities from September 2022 to December 2024
- Runway for company to continue to recover post COVID-19 and grow value for all stakeholders


Commitments of c.52% SSNs received for Exchange Offer, selecting all-Note option

Consents received by 17th February 2021 will be eligible for 0.5% ‘early bird’ consent fee

Background to Exchange Offer

Maturity extension request follows months of re-building post COVID-19 disruption

Key Milestones



- COVID-19 impact well managed, but created a setback in performance and deleveraging trajectory
- Company's ability to stabilise, recover and grow has left it well placed to execute its growth plans, with €114m liquidity at Q4 20 providing stable platform
- Long-term performance expected to be strong as markets recover combined with strategic and operational initiatives providing continued de-leveraging
- Balta requires operational flexibility in terms of its Note maturity to de-risk the capital structure and focus on sustained recovery

Key Terms of Exchange Offer and Benefits

Proposed extension terms offers a mutually beneficial deal for Balta and Noteholders

Key Terms

- **New Note with revised maturity of 31 December 2024**
- Pro rata share of **cash out option at 98c¹⁾**
- **75bps** Consent Fee, of which **50bps** early bird fee
- **100bps** payment in kind increase in coupon; increasing to **300bps** PIK from March 2024
- **200bps** soft call premium for first 6 months. Thereafter par call until 15 March 2023, **200bps** call premium from 15 March 2023 to maturity
- Belgian Real estate valued at **€46m** provided as additional security to European SSRCF and Notes
- Documentation improvements for noteholders:
 - Negative pledge over remaining Belgian RE, except where required in support of strategic initiatives;
 - Removal of company's ability to designate restricted subsidiaries as unrestricted; and
 - Guarantor Coverage test to match European SSRCF

Key Benefits

- De-risk capital structure, focus on growth and refinancing
- Cash exit option for significant portion of Notes
- Enhanced returns for consenting SSNs
- Company incentivised to refinance ahead of maturity through escalating PIK and call premium structure
- Enhanced value provided to European SSRCF and Note security package
- Restricted potential for value-leakage from lender guarantor and security package

Successful Exchange offer would allow Balta to focus on continuing to deliver strong results while ensuring the Notes remain a well-performing credit

Timetable

20 business day duration of Exchange Offer

Key Dates

2 February 2021

Launch Exchange Offer

17 February 2021

Deadline for Early Consent Consideration

3 March 2021

Expiration of Exchange Offer

UK Scheme of Arrangement

UK Scheme of Arrangement to be launched if support of Noteholders representing at least 75% but less than 90% of outstanding SSNs received

Mid April

Convening hearing

Early May

Creditors' meeting

Mid May

Sanction hearing / scheme becomes effective

Further information

For any questions about the Exchange Offer, Consent Solicitation and Scheme Solicitation process, please contact Lucid Issuer Services Limited

Attention: Sunjeeve Patel / Paul Kamminga

Address: Tankerton Works, 12 Argyle Walk, WC1H 8HA, London, UK

Telephone: +44 207 704 0880

Email: balta@lucid-is.com

For questions related to the terms of the Exchange Offer, please contact Moelis & Company:

Attention: Charles Noel-Johnson

Daniel Gibney

Email: Charles.Noel-Johnson@moelis.com

Daniel.Gibney@moelis.com

For other information, or questions for the company, please contact:

Maarten Van Hoecke

Corporate Finance & Investor Relations Director

Investor.Relations@baltagroup.com



 **balta**

Supplementary Materials

Terms of Proposal

TERMS	COMMENTS
BORROWER	<ul style="list-style-type: none"> LSF9 Balta Issuer S.à r.l
INSTRUMENT	<ul style="list-style-type: none"> 7.75% Senior Secured Notes due 2022 (“SSNs”)
Exchange Offer	<ul style="list-style-type: none"> Choice between; i) Exchange all SSNs for equivalent face value of New Notes due 31 December 2024; or ii) Exchange SSNs for a portion of €39.2m cash allocated pro rata to SSNs selecting this option at a price of €980 cash for each €1,000 principal SSNs tendered, with remainder of SSNs exchanged for New Notes at full face value
CONSENT FEE	<ul style="list-style-type: none"> 0.75% payable by reference to the commitments of each Consenting Noteholder exchanged for New Notes of which 0.5% ‘early bird’. No fee payable in respect of SSNs exchanged for cash
NEW NOTES MARGIN	<ul style="list-style-type: none"> Increase to 8.75% total coupon, consisting of existing 7.75% cash coupon and 1% Payment In Kind until 15 March 2024 From 15 March 2024 increase to 10.75% total coupon, consisting of existing 7.75% cash coupon and 3% Payment In Kind
NEW NOTES CALL PREMIUM	<ul style="list-style-type: none"> 102 (2%) soft call premium for first 6 months (102 for a refinancing, 100 for all other redemptions) Thereafter, par call until 15 March 2023 102 (2%) call premium from 15 March 2023
MATURITY / TERMINATION DATE	<ul style="list-style-type: none"> Extension of the maturity date of the SSNs to 31 December 2024 for New Notes
NEW NOTES DOCUMENTATION AMENDMENTS	<ul style="list-style-type: none"> Removal of provision which allows the issuer to designate any restricted subsidiary to be an unrestricted subsidiary Guarantor coverage test to be inserted into indenture, and will be substantially the same as under European SSRFCF
SECURITY ENHANCEMENTS	<ul style="list-style-type: none"> Security over Waregem real estate and the remainder of Wielsbeke real estate to European SSRFCF lenders and Noteholders (may be released in support of strategic programmes); and Negative pledge over Belgian real estate subject to permitted purposes in support of the strategic objectives

Capitalization Table (Dec-20)

FACILITY	SIZE (€m)	COMMENTS
EUROPEAN SSRFCF	56	▪ Renegotiated in Sep-20, fully drawn
BENTLEY RCF	7	▪ €7m (\$9m) drawn, total facility size of €15m (\$18m)
SENIOR SECURED NOTES	235	▪ Subject to Amend and Extend Proposal
FINANCE LEASES & SLB	50	▪ Excludes €36m of IFRS16
TOTAL BALTA AND BENTLEY GROSS DEBT ¹	348	▪ Group Net Debt excluding IFRS16 of €36m and including accrued SSN interest of €5m
CASH ²	106	▪ Balta and Bentley Cash
NET DEBT ¹	247	▪ Group Net Debt excluding IFRS16 of €36m and including accrued SSN interest of €5m

METRICS

ADJUSTED EBITDA	68	▪ Based on latest estimate of FY20 performance – subject to audit review
LEVERAGE ^{1 3}	4.2x	▪ Group net leverage ratio based on latest estimate of FY20 Adjusted EBITDA excl. IFRS16

Note: Numbers may not add up due to rounding

¹ Includes accrued interest of €5m, excludes IFRS16 of €36m

² Excludes undrawn facilities

³ Based on latest estimate of FY20 Adjusted EBITDA excl. IFRS16 impact (as defined in our financing agreements) of €59m – subject to audit review